Orally effective methylphenidate extended release powder and aqueous suspension product
DC CAFCFirst Claim
1. A methylphenidate aqueous extended release oral suspension consisting of a combination of(a) a sustained release, cured, water-permeable, water-insoluble, non-ionic, polymeric diffusion barrier coated methylphenidate-ion exchange resin complex—
- matrix, wherein the cured diffusion barrier coating comprises about 70 to about 90% polyvinylacetate, about 2.5 to about 15% of a plasticizer, and a stabilizer,(b) an immediate release methylphenidate component,(c) at least 50% by weight water based on the total weight of the liquid component of the suspension, and(d) pharmaceutically acceptable excipients,wherein said suspension has a pH of about 3.5 to about 5, and said suspension providing a therapeutically effective plasma profile of d-methylphenidate for about 12 hours and a single mean plasma concentration peak for d-methylphenidate.
4 Assignments
Litigations
0 Petitions
Accused Products
Abstract
An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
-
Citations
30 Claims
-
1. A methylphenidate aqueous extended release oral suspension consisting of a combination of
(a) a sustained release, cured, water-permeable, water-insoluble, non-ionic, polymeric diffusion barrier coated methylphenidate-ion exchange resin complex— - matrix, wherein the cured diffusion barrier coating comprises about 70 to about 90% polyvinylacetate, about 2.5 to about 15% of a plasticizer, and a stabilizer,
(b) an immediate release methylphenidate component, (c) at least 50% by weight water based on the total weight of the liquid component of the suspension, and (d) pharmaceutically acceptable excipients, wherein said suspension has a pH of about 3.5 to about 5, and said suspension providing a therapeutically effective plasma profile of d-methylphenidate for about 12 hours and a single mean plasma concentration peak for d-methylphenidate. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- matrix, wherein the cured diffusion barrier coating comprises about 70 to about 90% polyvinylacetate, about 2.5 to about 15% of a plasticizer, and a stabilizer,
-
9. An aqueous methylphenidate extended release suspension having a pH in the range of about 4 to about 4.5 comprising at least about 80% water and a combination of (a) a sustained release, cured, water-permeable, water-insoluble, non-ionic, polymeric diffusion barrier coated methylphenidate-ion exchange resin complex-matrix, wherein the cured diffusion barrier coating comprises about 70 to about 90% polyvinylacetate, about 2.5 to about 15% of plasticizer, and a stabilizer, and said methylphenidate-ion exchange resin complex is in a matrix formed by granulating said complex with at least one hydrophilic or hydrophobic polymeric matrix forming component and (b) an immediate release uncoated methylphenidate-ion exchange resin complex, wherein the coated methylphenidate-ion exchange resin complex-matrix of (a) are particulates having an average size range of about 100 microns to about 250 microns, said suspension providing a single mean plasma concentration peak for d-methylphenidate and a therapeutically effective plasma profile of d-methylphenidate for about twelve hours.
-
10. A methylphenidate extended release powder blend, said extended release powder blend consisting of (i) an immediate release methylphenidate component;
- (ii) a cured water-permeable, high tensile strength, water insoluble, non-ionic, sustained release diffusion barrier coating comprising about 70 to about 90% polyvinylacetate polymer, about 2.5 to about 15% of a plasticizer, and a stabilizer over a methylphenidate—
ion exchange resin complex-matrix;
(iii) a water soluble buffering agent which adjusts the pH of an aqueous suspension formed by admixing said extended release powder blend with water to a pH in the range of about 3.5 to about 5; and
(iv) optional pharmaceutical excipients, said powder blend providing a therapeutically effective plasma profile of d-methylphenidate for about 12 hours hours and a single mean plasma concentration peak for d-methylphenidate. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
- (ii) a cured water-permeable, high tensile strength, water insoluble, non-ionic, sustained release diffusion barrier coating comprising about 70 to about 90% polyvinylacetate polymer, about 2.5 to about 15% of a plasticizer, and a stabilizer over a methylphenidate—
- 26. A solid dose unit in the form of a tablet or capsule comprising a methylphenidate extended release powder blend, said extended release powder blend comprising (i) an immediate release methylphenidate component and (ii) a cured, water-permeable, high tensile strength, water insoluble, non-ionic sustained release polymeric diffusion barrier coated methylphenidate-ion exchange resin complex-matrix, said cured diffusion barrier coating comprising about 70 to about 90% polyvinylacetate, about 2.5 to about 15% of a plasticizer, and a stabilizer, and being present in an amount of about 20% to about 45% weight gain to the methylphenidate-ion exchange resin complex-matrix based the weight of the matrix pre-coating, and wherein (i) and (ii) are provided in a ratio of about 10 to about 30 parts methylphenidate as provided in the immediate release component (i) to about 70 to about 90 parts by weight methylphenidate as provided in sustained release (ii), based on the total weight of methylphenidate in the extended release powder blend, said solid dose unit providing a single mean plasma concentration peak for d-methylphenidate and a therapeutically effective plasma profile of d-methylphenidate for about twelve hours.
Specification